The Michael J. Fox Foundation will do whatever it takes to speed promising Parkinson's research toward clinical testing and patients. While our strong emphasis is on translational and clinical research, we also fund high-risk/high-reward discovery work to help keep novel approaches flowing into the drug development pipeline. New funding initiatives are announced throughout the year. Sign up to receive e-mail alerts whenever a new program is announced.
Please help us continually make our Web site better by completing our short survey (estimated completion time: 2-3 minutes). Your feedback will improve the site’s overall utility and ease of navigation. Thank you.
Pipeline Programs
Pipeline programs, which include the annually recurring Edmond J. Safra Core Programs for PD Research, address critical gaps to keep new scientific hypotheses flowing into, and forward on, the therapeutics development pipeline. We provide fast money for high-risk ideas under the Rapid Response Innovation Awards. Focused efforts for early-stage pre-clinical work can be funded under Target Validation and Novel Approaches to Drug Discovery for PD. Early-stage interventional trials are funded under the Clinical Intervention Awards. Funding exclusively for industry pre-clinical projects is available through the Therapeutics Development Initiative.
For more information on any MJFF program, scroll down and click on one of the program boxes below.
Discovery
Studies examining cell biological, biochemical pathways implicated in PD.
Translational
Applied pre-clinical research toward development of new therapies.
Clinical
Studies involving recruitment of human subjects or use of patient biosamples.
Rapid Response Innovation Awards An Edmond J. Safra Core Program for PD Research
No deadline; applications accepted at any time
Rapid Response Innovation Awards
Grants to support projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of Parkinson’s disease. Funding decisions made within six weeks of application receipt. Applications may be submitted at any time.
Target Validation An Edmond J. Safra Core Program for PD Research
Deadline
January 6, 2009
Target Validation
Awards to support investigator-initiated applications designed to validate the therapeutic potential of scientific discoveries and to push them one step closer to the clinic.
Clinical Intervention Awards An Edmond J. Safra Core Program for PD Research
Deadline
March 12, 2009
Clinical Intervention Awards
Funding to conduct novel or critical clinical intervention trials of promising therapeutic approaches that can significantly and fundamentally improve treatments for PD. Ideal proposals will be those that focus on well-designed and rigorous clinical trials testing potentially high-impact approaches.
Novel Approaches to Drug Discovery for Parkinson's Disease A Collaboration with Elan Pharmaceuticals, Inc.
Deadline
February 10, 2009
Novel Approaches to Drug Discovery for Parkinson's Disease
Funding to convert and further develop promising biological targets into novel disease-modifying therapeutic strategies.
Therapeutics Development Initiative Industry-exclusive funding for preclinical PD research
Deadline
January 20, 2009
Therapeutics Development Initiative
Industry-exclusive funding to support preclinical Parkinson’s disease research at for-profit institutions.
For more information on how we allocate funds to benefit people living with PD, see The MJFF Funding Philosophy. To read about grants previously awarded under any of these programs, use our Searchable Database of Funded Grants. Our driving goal is to fund the right science at the right time to advance progress toward improved PD treatments. If, after reading through the materials available here and elsewhere on our site, you are unsure of which program would best fit your project, please contact our Scientific Staff.
